Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

trialsTrialRecruiting

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

A phase 1/2 trial of Pucotenlimab, Bevacizumab in hepatocellular carcinoma, run by Lepu Biopharma Co., Ltd., now recruiting.

Overview Connected5

Overview

MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II) is a phase 1/2 interventional study registered as NCT07479485 by Lepu Biopharma Co., Ltd., with 160 participants planned, started 2026-04-08 and due to reach its primary completion in 2028-04. Interventions recorded: MRG006A, Pucotenlimab, Bevacizumab, PD1/VEGF antibody, TKI. Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.

Setting

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Phase

Phase 1/2

Sponsor

Lepu Biopharma Co., Ltd.

Registry

Started

2026-04-08

Enrolled

160 enrolled

Connected

Similar pages

Trial
Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma
Shares Lepu Biopharma, Pucotenlimab.
Trial
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Trial
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Trial
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Trial
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Trial
A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Advanced hepatocellular carcinoma (BCLC C), Bevacizumab, Hepatocellular carcinoma.
Trial
A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcin
Shares Lepu Biopharma, Pucotenlimab.
Trial
A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.

cancers

Advanced hepatocellular carcinoma (BCLC C)Hepatocellular carcinoma

drugs

ApprovedMonoclonal antibody (anti-VEGF)

Bevacizumab · Avastin (and biosimilars)

ApprovedAnti-PD-1 monoclonal antibody, intravenous

companies

Evidence strength24/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 1/2+8
160 enrolled+11
No structured primary endpoint0
Result: recruiting0
No independent replication recorded0
A linked product is approved+5

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-18 · Jude Gomila · Link 1,018 registry trials to cancer subtype pages by dri… · diff · file

Sources & links

ClinicalTrials.gov NCT07479485

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Hepatocellular carcinoma
Advanced hepatocellular carcinoma (BCLC C)

Products

Pucotenlimab
Bevacizumab

Companies

Lepu Biopharma

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct07479485/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct07479485.

WebMCP tools registered on this page: onco_search, onco_get_entity.